| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $22.49B | +1.8% |
| Cost of Revenue | $16.50B | +19.7% |
| R&D Expense | $686.0M | +11.2% |
| SG&A Expense | $3.20B | -3.0% |
| Operating Income | $2.65B | +15.2% |
| Interest Expense | $580.0M | +60.2% |
| Pre-tax Income | $2.27B | +9.1% |
| Income Tax | $1.06B | +64.9% |
| Net Income | $5.60B |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.97B | -60.4% |
| Accounts Receivable | $2.65B | +6.9% |
| Inventory | $2.30B | +3.7% |
| Current Assets | $9.89B | -47.3% |
| Total Assets | $37.40B | +14.0% |
| Current Liabilities | $7.89B | +14.5% |
| Long-term Debt | $11.03B | -22.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $563.0M | -78.4% |
| Investing Cash Flow | -$2.02B | -206.8% |
| Financing Cash Flow | -$4.64B | -200.5% |
| +315.4% |
| EPS (Basic) | $6.24 | +287.6% |
| EPS (Diluted) | $6.15 | +289.2% |
| Total Liabilities |
| $23.01B |
| -3.4% |
| Stockholders' Equity | $14.39B | +59.9% |